Biotech IPO

This Oncology Company’s “Platform In A Pill” Cancer Treatment Could Be A Massive Opportunity

by Alex Clarke
April 5, 2021April 17, 2021

RAS mutations are the initiating genetic events in many cancers – and have proven to be extremely difficult to target. With its lead compound, however, the oncology company featured in today’s article is “looking to become the backbone of treatment for RAS-driven cancers.

This Recent Biotech IPO Has The Right Story At The Right Time – And The Right Pattern

by Alex Clarke
January 10, 2021April 17, 2021

The author of today’s article notes that high-profile IPOs typically follow a pattern – and given this pattern, he is bullish on “a biotech stock that went public just under a month ago with a story that perfectly fits the times, and whose stock has followed exactly that pattern.”